secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0000917520-22-000058
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra to acquire SIA for up to $140M; plans $150M share buyback
-----------------------------------------------------------------

- Integra buys SIA for $50M at closing plus up to $90M in milestones; deal expected to close by end of 2022.
- SIA 2022E revenue ~$5M; gross margin >75%. Acquisition dilutive ~$0.06 in Year 1, accretive in Year 3.
- ROIC expected to exceed 10% by Year 5 (2027).
- Plans $150M share repurchase starting early 2023 to largely offset Year 1 dilution.
- No FDA-approved surgical matrices for IBBR; Integra's SurgiMend PMA under review, DuraSorb IDE ~70% enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000058/0000917520-22-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000058/iart-20221130.htm
  HTML page:      https://secwatch.observer/filing/0000917520-22-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer